Shares of Tango Therapeutics Inc. (TNGX) touched an all-time high of $18.97 yesterday as the company progresses through 2026 with a focused commitment to execution, building on the substantial advancements across its development portfolio in 2025.
This clinical-stage biotechnology company is developing the next generation of precision cancer medicines. Its lead drug candidate is Vopimetostat, also known as TNG462, a potent and selective PRMT5 (Protein Arginine Methyltransferase 5) inhibitor. PRMT5 is an enzyme that is often overactive in certain cancers, helping tumor cells grow and survive.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.